A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1630-1636

  Hainsworth, John D ^a   Cebotaru, Cristina L ^b   Kanarev, Vladimir ^c   Ciuleanu, Tudor E ^b   Damyanov, Danail ^d   Stella, Phillip ^e   Ganchev, Hristo ^f   Pover, Gillian ^g   Morris, Clive ^g   Tzekova, Valentina ^h  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^c Chemotherapy Department   (Bulgaria)

^d National Oncology Center Bulgaria   (Bulgaria)

^e ST JOSEPH MERCY HOSPITAL   (United States)

^f UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

^g ASTRAZENECA   (United Kingdom)

^h MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

AZD6244; Clinical trial; MEK inhibitor; Non small cell lung cancer; Phase II

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; CORTICOSTEROID; CYANOCOBALAMIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FOLIC ACID; PEMETREXED; PLATINUM; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 77958198647     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e8b3a3     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. American Cancer Society. Cancer facts & figures 2009. Available at: http://www.cancer.org/downloads/STT/500809web.pdf. Accessed June 25, 2009.
3. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-3024. (Pubitemid 46606280)
4. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemother-apy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
5. Wang D, Boerner SA, Winkler JD, et al. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 2007;1773:1248-1255. (Pubitemid 47161034)
6. Zebisch A, Czernilofsky AP, Keri G, et al. Signaling through RASRAF-MEK-ERK: from basics to bedside. Curr Med Chem 2007;14: 601-623. (Pubitemid 46477731)
7. Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 1999;20:1507-1510. (Pubitemid 29385437)
8. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 2001;19:448-457. (Pubitemid 32112858)
9. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007;13:1576-1583. (Pubitemid 46450450)
10. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-2146.
11. NCCN Practice Guidelines in Oncology™. Non-small cell lung cancer (version 2.2009). Available at: http://www.nccn.org/professionals/physician-gls/ f-guidelines.asp. Accessed June 25, 2009.
12. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
14. Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005;23:7199-7206. (Pubitemid 46260307)
15. Stone A, Wheeler C, Carroll K, et al. Optimizing randomized phase II trials assessing tumor progression. Contemp Clin Trials 2007;28:146-152. (Pubitemid 44937877)
16. Carroll KJ. Analysis of progression-free survival in oncology trials: some common statistical issues. Pharm Stat 2007;6:99-113.
17. Bearz A, Garassino I, Cavina R, et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer 2008;60:240-245. (Pubitemid 351609151)
18. Cullen MH, Zatloukal P, Sorenson S, et al. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 2008;19:939-945. (Pubitemid 351627311)
19. Okabe T, Kubota K, Tamura T, et al. Prognostic factors affecting survival on pretreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)-subgroup analysis in a randomized Ph II study of pemetrexed 500 mg/m2 and 1000 mg/m2. Eur J Cancer Suppl 2007;5:376.
20. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2:S851.
21. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-263.
22. ALIMTA- prescribing information. Eli Lilly and Company. Available at: http://pi.lilly.com/us/alimta-pi.pdf. Accessed August 6, 2009.
23. Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6: 2209-2219. (Pubitemid 47294749)
24. Dummer R, Robert C, Chapman PB, et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multi-center, phase II study. J Clin Oncol 2008;26:Abstract 9033.